
In recent months the focus on the need to develop new drugs and fund new treatments for rare diseases has …
Rare disease specialist firm Alexion is splashing out $8.4 billion to buy fellow US orphan drug developer Synageva biopharmaceuticals. The …

Shire is to acquire rare diseases firm NPS Pharma to enhance its profile following the collapse of its deal with …

